- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT07363759
ISOVUE Comparative Trial (ISOVUE)
January 14, 2026 updated by: Rush University Medical Center
ISOVUE Contrast for Intraoperative Assessment of Discectomy Quality in TLIF: A Prospective Randomized Trial
This study aimed to investigate a novel technique for intraoperative quantitative and qualitative feedback during discectomy and endplate preparation in TLIF.
Study Overview
Status
Completed
Intervention / Treatment
Detailed Description
The purpose of this study was to introduce a novel surgical technique using ISOVUE-300M contrast dye for intraoperative visualization of discectomy progress and to test the value of this technique by comparing outcomes of two patient cohorts.
The investigators hypothesize that the standard TLIF technique results in a surprisingly low percentage of effective disc preparation, even when performed by an experienced TLIF surgeon.
Secondly, the investigators hypothesize that by using intraoperative visual feedback to guide a second discectomy pass that the extent of disc space preparation can be substantially improved compared to patients where visual feedback is not available.
Lastly, the investigators aim to conduct a clinical outcomes analysis evaluating radiographic and complication outcomes.
To the best of the authors' knowledge, this prospective study is the first to evaluate differences in disc space preparation using a novel contrast-based technique while also providing clinical outcomes.
Study Type
Interventional
Enrollment (Actual)
56
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Illinois
-
Chicago, Illinois, United States, 60612
- Rush University Medical Center
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Yes
Description
Inclusion Criteria:
- Patients undergoing open circumferential transforaminal lumbar interbody fusion or midline cortical TLIF for degenerative spondylolisthesis
Exclusion Criteria:
- All not in the group above
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Placebo Comparator: Observation
In the Observation group, after initial discectomy and endplate preparation, ISOVUE-300M contrast was administered into the disc space and orthogonal anterior-posterior and lateral radiographs were obtained.
The case then proceeded with graft and cage insertion without additional disc excision or endplate work.
|
In the Observation group, after initial discectomy and endplate preparation,ISOVUE-300M contrast was administered into the disc space and orthogonal anterior-posterior and lateral radiographs were obtained.
The case then proceeded with graft and cage insertion without additional disc excision or endplate work.
|
|
Experimental: Feedback
In the Feedback group, the surgeon was permitted to utilize the ISOVUE imaging as a feedback mechanism to then re-prepare the disc space prior to final graft/cage insertion.
An additional dose of ISOVUE-300M was administered into the disc space with repeat radiographs obtained prior to grafting/cage insertion to demonstrate the effect of the second pass of disc and cartilage removal.
|
In the Feedback group, the surgeon was permitted to utilize the ISOVUE imaging as a feedback mechanism to then re-prepare the disc space prior to final graft/cage insertion.
An additional dose of ISOVUE-300M was administered into the disc space with repeat radiographs obtained prior to grafting/cage insertion to demonstrate the effect of the second pass of disc and cartilage removal.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Anteroposterior Plane Clearance
Time Frame: Immediately after Discectomy
|
Disc space clearance in the anteroposterior (AP) plane at the index level measured on oblique radiographs.
|
Immediately after Discectomy
|
|
Mediolateral Plane Clearance
Time Frame: Immediately after Discectomy/Excision Intraoperatively
|
Disc space clearance in the mediolateral (ML) plane as measured by oblique radiographs.
|
Immediately after Discectomy/Excision Intraoperatively
|
|
Visual Analog Scale
Time Frame: First Postoperative Clinic Appointment (within first 6 weeks)
|
Visual Analog Scale survey assessing leg pain and back pain
|
First Postoperative Clinic Appointment (within first 6 weeks)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Lumbar Lordosis
Time Frame: Immediately after Discectomy Intraoperatively
|
Lumbar Lordosis as measured by oblique radiographs.
|
Immediately after Discectomy Intraoperatively
|
|
Pelvic Incidence
Time Frame: Immediately after Discectomy Intraoperatively
|
Pelvic incidence (PI) as measured by oblique radiographs.
|
Immediately after Discectomy Intraoperatively
|
|
Disc Height
Time Frame: Immediately after Discectomy Intraoperatively
|
Disc height at the index level as identified by oblique radiographs.
|
Immediately after Discectomy Intraoperatively
|
|
Oswestry Disability Index
Time Frame: First Postoperative Clinic Appointment (within first 6 weeks)
|
Oswestry Disability Index survey describing disability as a result of spinal conditions.
|
First Postoperative Clinic Appointment (within first 6 weeks)
|
|
Short Form Survey
Time Frame: First Postoperative Clinic Appointment (within first 6 weeks)
|
SF-12 survey asking patient views about health
|
First Postoperative Clinic Appointment (within first 6 weeks)
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
- Lan T, Hu SY, Zhang YT, Zheng YC, Zhang R, Shen Z, Yang XJ. Comparison Between Posterior Lumbar Interbody Fusion and Transforaminal Lumbar Interbody Fusion for the Treatment of Lumbar Degenerative Diseases: A Systematic Review and Meta-Analysis. World Neurosurg. 2018 Apr;112:86-93. doi: 10.1016/j.wneu.2018.01.021. Epub 2018 Jan 31.
- de Kunder SL, van Kuijk SMJ, Rijkers K, Caelers IJMH, van Hemert WLW, de Bie RA, van Santbrink H. Transforaminal lumbar interbody fusion (TLIF) versus posterior lumbar interbody fusion (PLIF) in lumbar spondylolisthesis: a systematic review and meta-analysis. Spine J. 2017 Nov;17(11):1712-1721. doi: 10.1016/j.spinee.2017.06.018. Epub 2017 Jun 21.
- Katuch V, Grega R, Knorovsky K, Banoci J, Katuchova J, Sasala M, Ivankova H, Kapralova P. Comparison between posterior lumbar interbody fusion and transforaminal lumbar interbody fusion in the management of lumbar spondylolisthesis. Bratisl Lek Listy. 2021;122(9):653-656. doi: 10.4149/BLL_2021_105.
- Reitman CA, Anderson DG, Fischgrund J. Surgery for degenerative spondylolisthesis: open versus minimally invasive surgery. Clin Orthop Relat Res. 2013 Oct;471(10):3082-7. doi: 10.1007/s11999-013-3171-8. Epub 2013 Jul 20. No abstract available.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
April 11, 2019
Primary Completion (Actual)
June 19, 2023
Study Completion (Actual)
June 19, 2023
Study Registration Dates
First Submitted
January 7, 2026
First Submitted That Met QC Criteria
January 14, 2026
First Posted (Actual)
January 23, 2026
Study Record Updates
Last Update Posted (Actual)
January 23, 2026
Last Update Submitted That Met QC Criteria
January 14, 2026
Last Verified
January 1, 2026
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 18072502-IRB02
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
IPD Plan Description
The investigators will consider sharing if contacted with reasonable requests.
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
Yes
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Lumbar Degenerative Disc Disease
-
Providence Medical Technology, Inc.RecruitingRadiculopathy Lumbar | Degenerative Lumbar Disc DiseaseUnited States
-
NuVasiveCompleted
-
Silony Medical GmbHActive, not recruitingDegenerative Cervical Disc Disease | Degenerative Lumbar DiseasesUnited States
-
NuVasiveCompleted
-
Assistance Publique - Hôpitaux de ParisTerminatedCervical Degenerative Disc Disease | Kyphosis | Lumbar Degenerative Disc DiseaseFrance
-
Spine BioPharma, IncMCRAActive, not recruitingLumbar Degenerative Disc DiseaseUnited States
-
Synthes USA HQ, Inc.CompletedLumbar Degenerative Disc Disease
-
NuVasiveCompletedLumbar Degenerative Disc DiseaseUnited States
-
Spineology, IncCompletedLumbar Degenerative Disc DiseaseUnited States
-
Alphatec Spine, Inc.TerminatedLumbar Degenerative Disc DiseaseUnited States
Clinical Trials on ISOVUE 300 Observation
-
GE HealthcareQuintiles, Inc.; Physician Reference LaboratoryCompleted
-
GE HealthcareQuintiles, Inc.; Covance; ABX CRO; Examination Management Services Inc.; Averion...TerminatedDiabetes Mellitus | Renal InsufficiencyUnited States, United Kingdom
-
Bracco Diagnostics, IncCompleted
-
Bracco Diagnostics, IncCompleted
-
GE Healthcarei3 StatprobeCompleted
-
University of ArizonaTerminatedBreast CancerUnited States
-
GE Healthcarei3 StatprobeCompletedPatient Comfort and SafetyUnited States
-
Bracco Diagnostics, IncCompleted
-
Bracco Diagnostics, IncTerminated